Ruxolitinib discontinuation syndrome: incidence, risk factors and management in 251 patients with myelofibrosis
Contributor Blood Cancer
Behind the paper

Ruxolitinib discontinuation syndrome: incidence, risk factors and management in 251 patients with myelofibrosis

Go to the profile of Francesca Palandri
Francesca Palandri
Jan 15, 2021